Pulse Biosciences Q2 net loss widens, cash position strengthens

Pulse Biosciences

06/08/2026 21:21

Overview
Bioelectric medicine company's Q2 2026 revenue grew sequentially during controlled commercial launch
GAAP net loss for Q2 widened yr/yr due to higher clinical and compensation expenses
Company raised $46.8 mln in net proceeds through ATM program, strengthening cash position

Outlook
Company expects to complete NANOPULSE-AF study enrollment by early Q4 2026
Pulse Biosciences plans CE Mark submissions for cardiac catheter and surgical systems in H2 2026
Company expects NANOCLAMP-AF study enrollment to complete by end of H1 2027

Result Drivers
CLINICAL PROGRAM INVESTMENT - Increased costs driven by expanded clinical trial activity and compensation expenses
CONTROLLED COMMERCIAL LAUNCH - Sequential revenue growth during controlled launch while focusing on market development
LIMITED CUSTOMER BASE - Company focused on procedural utilization within a limited customer base based on clinical results

Company press release: ID:nBw8BjFdNa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$24.66 mln
 
Q2 Income from Operations
 
-$25.27 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Pulse Biosciences Inc is $32.00, about 15.6% below its August 5 closing price of $37.90

Reuters Recommended Reads
Aug 5 - UK's LivaNova Q2 revenue beats estimates; lifts 2026 outlook
Aug 5 - Myomo Q2 adjusted EBITDA loss narrows, beats expectations
Aug 4 - Procept BioRobotics Q2 revenue beats estimates on HYDROS demand

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)